Literature DB >> 31672251

Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European Regulators.

Frank Holtkamp1, Hrefna Gudmundsdottir2, Romaldas Maciulaitis3, Norbert Benda4, Andrew Thomson5, Thorsten Vetter6.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31672251     DOI: 10.1053/j.ajkd.2019.07.019

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  6 in total

Review 1.  Targeting inflammation for the treatment of Diabetic Kidney Disease: a five-compartment mechanistic model.

Authors:  Alexis Hofherr; Julie Williams; Li-Ming Gan; Magnus Söderberg; Pernille B L Hansen; Kevin J Woollard
Journal:  BMC Nephrol       Date:  2022-06-13       Impact factor: 2.585

2.  Allograft Function as Endpoint for Clinical Trials in Kidney Transplantation.

Authors:  Luuk Hilbrands; Klemens Budde; Maria Irene Bellini; Fritz Diekmann; Lucrezia Furian; Josep Grinyó; Uwe Heemann; Dennis A Hesselink; Alexandre Loupy; Rainer Oberbauer; Liset Pengel; Marlies Reinders; Stefan Schneeberger; Maarten Naesens
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

Review 3.  Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.

Authors:  Ravi B Patel; Jozine M Ter Maaten; João Pedro Ferreira; Finnian R McCausland; Sanjiv J Shah; Patrick Rossignol; Scott D Solomon; Muthiah Vaduganathan; Milton Packer; Aliza Thompson; Norman Stockbridge; Faiez Zannad
Journal:  Circulation       Date:  2021-01-07       Impact factor: 29.690

Review 4.  Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.

Authors:  Lesley A Inker; Hiddo J L Heerspink; Hocine Tighiouart; Juhi Chaudhari; Shiyuan Miao; Ulysses Diva; Alex Mercer; Gerald B Appel; James V Donadio; Jürgen Floege; Philip K T Li; Bart D Maes; Francesco Locatelli; Manuel Praga; Francesco P Schena; Andrew S Levey; Tom Greene
Journal:  Am J Kidney Dis       Date:  2021-03-26       Impact factor: 11.072

5.  Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.

Authors:  Sebastiaan Camiel Goulooze; Hiddo J L Heerspink; Martijn van Noort; Nelleke Snelder; Meike Brinker; Joerg Lippert; Thomas Eissing
Journal:  Clin Pharmacokinet       Date:  2022-05-05       Impact factor: 5.577

6.  Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.

Authors:  Satoshi Miyamoto; Hiddo J L Heerspink; Dick de Zeeuw; Masao Toyoda; Daisuke Suzuki; Takashi Hatanaka; Tohru Nakamura; Shinji Kamei; Satoshi Murao; Kazuyuki Hida; Shinichiro Ando; Hiroaki Akai; Yasushi Takahashi; Daisuke Koya; Munehiro Kitada; Hisashi Sugano; Tomokazu Nunoue; Akihiko Nakamura; Motofumi Sasaki; Tatsuaki Nakatou; Kei Fujimoto; Daiji Kawanami; Takashi Wada; Nobuyuki Miyatake; Michihiro Yoshida; Kenichi Shikata
Journal:  Diabetes Obes Metab       Date:  2022-05-18       Impact factor: 6.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.